Main Article Content


Stroke is basically a medical condition where there is low blood flow to the brain and thus results in cell death. It remains the second most common cause of death. Stroke patients also have different comorbidities on an average where they are prescribed with 6-10 medicines. This increase the chances for drug-related problems (DRPs) and adverse drug events (ADEs) or adverse drug reactions (ADRs) and the interventions found during the follow up of stroke patients. Several studies finding of interventions in stroke patients and reconciliation are ways to reduce ADRs and improve medication use safety. Interventions and medical reconciliation (MR) address a wide array of potential medication-related issues, which is carefully planned that may be done by pharmacist or doctor or professional (or) physician. Here the aim was to access the impact of interventions which includes medications reconciliation and counselling of stroke patients and also identification and categorization of DRPs. Polypharmacy causing DRPs was statistically significant in all the regions inappropriate drug selection (2.85%), and dose selection (2.85%) was the primary cause of DRPs 85% partially solved. Epidemiologically of all the three regions (GNT, VIJ, RJY) in the total study population. Males are more affected than females. Majority of comorbidities like HTN(70.05%), and DM(47.01%)were in leading role causing stroke absorbed during interventions. Leaflet & patient counselling had prominent role in conducting medical reconciliation. Other health care professionals systematically find, differentiate & report interventions like (DRPs, ADRs, and causes).


Adverse drug events (ADEs) medical reconciliation (MR) patient counselling (PC) Adverse drug reactions (ADRs)

Article Details

How to Cite
Prakash A, Kalyan Rao B, Sujitha Sri K, Lakshman Naik R, Shaik Shahin Kouser, & Divya Y. (2020). Clinical pharmacist interventions in post stroke follow up patients in tertiary care hospital on coastal region. International Journal of Pharmaceutical Research and Life Sciences, 8(2), 45-52.